An independent reading of the global metabolic crisis — the diagnostics, the pharmacology, the geography, and the bill. Continuously aggregated from public datasets and clinical literature.
88,420,902
Real-time analysis of scripts written across U.S. tier-1 healthcare networks.
+4.73%
Projected median U.S. adult BMI shift by 2030 absent systemic intervention.
Five reference desks, each engineered as a standalone reading. Begin anywhere. The platform is non-linear by design — the epidemic does not unfold in chapters.
Compute your BMI alongside waist-to-height ratio, with categorical risk stratification across CDC and WHO frameworks.
Side-by-side analysis of dietary protocols, bariatric surgery, and GLP-1 receptor agonists. Efficacy, cost, side-effect profile.
Locate accredited bariatric centers, endocrinologists, and obesity-medicine specialists by zip code radius search.
What Medicare, Medicaid, and major commercial plans cover for weight-loss medication and bariatric procedures.
CDC adult obesity rates across 50 states and territories, with longitudinal context and disparity analysis.
GLP-1 receptor agonists do not negotiate with willpower. They rewire the satiety signal at the hypothalamic root, and slow gastric emptying as a peripheral reinforcement. The pharmacology is precise; the consequences are still being written.
The map of American obesity is not flat. It rises sharply in the South and the rural Midwest, where 23 states now report adult prevalence above 35%. Income, infrastructure, and food geography draw the contour lines.
"Obesity is not a moral failing. It is a predictable biological response to an engineered caloric environment. The remedy is therefore engineering, not shame."
At the cellular level, adipose tissue is an endocrine organ. It speaks — in leptin, in inflammation, in insulin resistance. The platform you are reading is an attempt to translate.
Continue to interventions →
